Back to search
FDAFDA · Food and drugs·Recall number Z-1233-2020

Dimension Vista Enzymatic Creatinine (ECREA) reagent, SMN 10700444

Published February 26, 2020 · Recall initiated: December 18, 2019

Summary

FDA records medical device Class II recall Z-1233-2020, published February 26, 2020 and initiated December 18, 2019. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Terminated; Reported quantity: 11,725 units; Lot: UDI Number: 00842768036262 Lots: All lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
US Nationwide
Lot
UDI Number: 00842768036262 Lots: All lots
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Dimension Vista Enzymatic Creatinine (ECREA) reagent, SMN 10700444 recalled?

Yes. FDA published recall Z-1233-2020 on February 26, 2020. Reported hazard: There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology.

What should I do if I have this product?

Voluntary: Firm initiated · Letter